

August 6, 2020

**VIA EDGAR SUBMISSION**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, NE  
Washington, DC 20549

Attention: Jeffrey Gabor

Re: Iterum Therapeutics plc  
Iterum Therapeutics Bermuda Limited  
Iterum Therapeutics International Limited  
Iterum Therapeutics US Limited  
Iterum Therapeutics US Holding Limited  
Registration Statement on Form S-1  
File No. 333-237326  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Iterum Therapeutics plc, Iterum Therapeutics Bermuda Limited, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited and Iterum Therapeutics US Holding Limited (collectively, the “Registrants”) hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-237326), as amended (the “Registration Statement”), so that it may become effective at 4:30 p.m., Eastern time, on August 10, 2020, or as soon as practicable thereafter.

---

Very truly yours,

ITERUM THERAPEUTICS PLC

By: /s/ Corey N. Fishman  
Name: Corey N. Fishman  
Title: Chief Executive Officer

ITERUM THERAPEUTICS BERMUDA LIMITED

By: /s/ Louise Barrett  
Name: Louise Barrett  
Title: Director

ITERUM THERAPEUTICS INTERNATIONAL LIMITED

By: /s/ Louise Barrett  
Name: Louise Barrett  
Title: Director

ITERUM THERAPEUTICS US LIMITED

By: /s/ Corey N. Fishman  
Name: Corey N. Fishman  
Title: Chief Executive Officer

ITERUM THERAPEUTICS US HOLDING LIMITED

By: /s/ Corey N. Fishman  
Name: Corey N. Fishman  
Title: Chief Executive Officer